AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Poly(A) polymerase gamma

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9BWT3

UPID:

PAPOG_HUMAN

Alternative names:

Neo-poly(A) polymerase; Polynucleotide adenylyltransferase gamma; SRP RNA 3'-adenylating enzyme; Signal recognition particle RNA-adenylating enzyme

Alternative UPACC:

Q9BWT3; B2RBH4; Q59G05; Q969N1; Q9H8L2; Q9HAD0

Background:

Poly(A) polymerase gamma, also known as Neo-poly(A) polymerase, plays a crucial role in the post-transcriptional adenylation of mRNA precursors and small RNAs, including SRP RNA and ribosomal 5S RNA. This enzyme's activity is pivotal for RNA stability and function, influencing the efficiency of mRNA translation and the cellular response to stress.

Therapeutic significance:

Understanding the role of Poly(A) polymerase gamma could open doors to potential therapeutic strategies. Its involvement in RNA processing and stability positions it as a key player in cellular homeostasis and disease mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.